|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Roque DR, Wysham WZ and Soper JT: The
surgical management of cervical cancer: An overview and literature
review. Obstet Gynecol Surv. 69:426–441. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
World Health Organization: Diagnosis and
treatment of invasive cervical cancer. Comprehensive Cervical
Cancer Control: A Guide to Essential Practice (2nd). (Geneva).
World Health Organization. 153–175. 2014.
|
|
4
|
Mabuchi S, Kuroda H, Takahashi R and
Sasano T: The PI3K/AKT/mTOR pathway as a therapeutic target in
ovarian cancer. Gynecol Oncol. 137:173–179. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Eskander RN and Tewari KS: Exploiting the
therapeutic potential of the PI3K-AKT-mTOR pathway in enriched
populations of gynecologic malignancies. Expert Rev Clin Pharmacol.
7:847–858. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cho DC: Targeting the PI3K/Akt/mTOR
pathway in malignancy: Rationale and clinical outlook. BioDrugs.
28:373–381. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Han Z, Wu K, Shen H, Li C, Han S, Hong L,
Shi Y, Liu N, Guo C, Xue Y, et al: Akt1/protein kinase B alpha is
involved in gastric cancer progression and cell proliferation. Dig
Dis Sci. 53:1801–1810. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Samuels Y and Ericson K: Oncogenic PI3K
and its role in cancer. Curr Opin Oncol. 18:77–82. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu J, Chen C and Zhao KN:
Phosphatidylinositol 3-kinase signaling as a therapeutic target for
cervical cancer. Curr Cancer Drug Targets. 13:143–156. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tanaka S, Tajima M, Tsukada M and Tabata
M: A comparative study on anti-inflammatory activities of the
enantiomers, shikonin and alkannin. J Nat Prod. 49:466–469. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mao X, Yu CR, Li WH and Li WX: Induction
of apoptosis by shikonin through a ROS/JNK-mediated process in
Bcr/Abl-positive chronic myelogenous leukemia (CML) cells. Cell
Res. 18:879–888. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Andújar I, Ríos JL, Giner RM and Recio MC:
Pharmacological properties of shikonin - a review of literature
since 2002. Planta Med. 79:1685–1697. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Andújar I, Recio MC, Giner RM and Ríos JL:
Traditional chinese medicine remedy to jury: The pharmacological
basis for the use of shikonin as an anticancer therapy. Curr Med
Chem. 20:2892–2898. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu JJ, Bao JL, Wu GS, Xu WS, Huang MQ,
Chen XP and Wang YT: Quinones derived from plant secondary
metabolites as anti-cancer agents. Anticancer Agents Med Chem.
133:456–463. 2013. View Article : Google Scholar
|
|
15
|
Wang R, Yin R, Zhou W, Xu D and Li S:
Shikonin and its derivatives: A patent review. Expert Opin Ther
Pat. 22:977–997. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rajasekar S, da Park J, Park C, Park S,
Park YH, Kim ST, Choi YH and Choi YW: In vitro and in vivo
anticancer effects of Lithospermum erythrorhizon extract on B16F10
murine melanoma. J Ethnopharmacol. 144:335–345. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yuan TL and Cantley LC: PI3K pathway
alterations in cancer: Variations on a theme. Oncogene.
27:5497–5510. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Song G, Ouyang G and Bao S: The activation
of Akt/PKB signaling pathway and cell survival. J Cell Mol Med.
9:59–71. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Martelli AM, Evangelisti C, Chiarini F and
McCubrey JA: The phosphatidylinositol 3-kinase/Akt/mTOR signaling
network as a therapeutic target in acute myelogenous leukemia
patients. Oncotarget. 1:89–103. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sarbassov DD, Guertin DA, Ali SM and
Sabatini DM: Phosphorylation and regulation of Akt/PKB by the
rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Martelli AM, Evangelisti C, Chiarini F,
Grimaldi C, Cappellini A, Ognibene A and McCubrey JA: The emerging
role of the phosphatidylinositol 3-kinase/Akt/mammalian target of
rapamycin signaling network in normal myelopoiesis and
leukemogenesis. Biochim Biophys Acta. 1803:991–1002. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Aimbetov R, Chen CH, Bulgakova O, Abetov
D, Bissenbaev AK, Bersimbaev RI and Sarbassov DD: Integrity of
mTORC2 is dependent on the rictor Gly-934 site. Oncogene.
31:2115–2120. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang S and Houghton PJ: Targeting mTOR
signaling for cancer therapy. Curr Opin Pharmacol. 3:371–377. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu G, Zhang W, Bertram P, Zheng XF and
McLeod H: Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR
pathway in common human tumors. Int J Oncol. 24:893–900.
2004.PubMed/NCBI
|
|
25
|
Welker ME and Kulik G: Recent syntheses of
PI3K/Akt/mTOR signaling pathway inhibitors. Bioorg Med Chem.
21:4063–4091. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gao N, Flynn DC, Zhang Z, Zhong XS, Walker
V, Liu KJ, Shi X and Jiang BH: G1 cell cycle progression and the
expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1
signaling in human ovarian cancer cells. Am J Physiol Cell Physiol.
287:C281–C291. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hay N and Sonenberg N: Upstream and
downstream of mTOR. Genes Dev. 18:1926–1945. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Takai N, Ueda T, Nishida M, Nasu K and
Narahara H: Beta-hydroxyisovalerylshikonin has a profound
anti-growth activity in human endometrial and ovarian cancer cells.
Gynecol Oncol. 109:107–114. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rao Z, Liu X, Zhou W, Yi J and Li SS:
Synthesis and antitumour activity of β-hydroxyisovalerylshikonin
analogues. Eur J Med Chem. 46:3934–3941. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hashimoto S, Xu M, Masuda Y, Aiuchi T,
Nakajo S, Cao J, Miyakoshi M, Ida Y, Nakaya K and Hashimoto S:
Beta-hydroxyisovalerylshikonin inhibits the cell growth of various
cancer cell lines and induces apoptosis in leukemia HL-60 cells
through a mechanism different from those of Fas and etoposide. J
Biochem. 125:17–23. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Takai N, Ueda T, Nishida M, Nasu K and
Narahara H: Anti-neoplastic effect of β-hydroxyisovalerylshikonin
on a human choriocarcinoma cell line. Mol Med Rep. 3:515–518. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nakaya K and Miyasaka T: A shikonin
derivative beta-hydroxyisovalerylshikonin, is an
ATP-non-competitive inhibitor of protein tyrosine kinases.
Anticancer Drugs. 14:683–693. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hashimoto S, Xu Y, Masuda Y, Aiuchi T,
Nakajo S, Uehara Y, Shibuya M, Yamori T and Nakaya K:
Beta-hydroxyisovalerylshikonin is a novel and potent inhibitor of
protein tyrosine kinases. Jpn J Cancer Res. 93:944–951. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kajimoto S, Horie M, Manabe H, Masuda Y,
Shibayama-Imazu T, Nakajo S, Gong XF, Obama T, Itabe H and Nakaya
K: A tyrosine kinase inhibitor, beta-hydroxyisovalerylshikonin,
induced apoptosis in human lung cancer DMS114 cells through
reduction of dUTP nucleotidohydrolase activity. Biochim Biophys
Acta. 1782:41–50. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Komi Y, Suzuki Y, Shimamura M, Kajimoto S,
Nakajo S, Masuda M, Shibuya M, Itabe H, Shimokado K, Oettgen P, et
al: Mechanism of inhibition of tumor angiogenesis by
beta-hydroxyisovalerylshikonin. Cancer Sci. 100:269–277. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nishida M, Nasu K, Ueda T, Yuge A, Takai N
and Narahara H: Beta-hydroxyisovalerylshikonin induces apoptosis
and G0/G1 cell-cycle arrest of endometriotic stromal cells: A
preliminary in vitro study. Hum Reprod. 21:2850–2856. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Boroughs LK and DeBerardinis RJ: Metabolic
pathways promoting cancer cell survival and growth. Nat Cell Biol.
17:351–359. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Castro J, Ribó M, Benito A and Vilanova M:
Mini-review: Nucleus-targeted ribonucleases as antitumor drugs.
Curr Med Chem. 20:1225–1231. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jin FP and Zhang M: Progress of
experimental researches on Chinese herbal compounds for inducing
tumor cell apoptosis. Chin J Integr Med. 16:565–571. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhao X, Ai M, Guo Y, Zhou X, Wang L, Li X
and Yao C: Poly I: C-induced tumor cell apoptosis mediated by
pattern-recognition receptors. Cancer Biother Radiopharm.
27:530–534. 2012. View Article : Google Scholar : PubMed/NCBI
|
